Quipt Home Medical Corp T.QIPT

Alternate Symbol(s): QIPT

Healthcare

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators, continuous positive airway pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) units; traditional and non-traditional medical respiratory equipment and services, and non-invasive ventilation equipment, supplies, and services. The Company's product offerings include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. Its products and services consist of sleep apnea and pap treatment, home ventilation, daily and ambulatory aides, and respiratory equipment rental.

TSX:QIPT - Post by User

Quipt Home Medical Corp

Bullboard Posts

Post by Tickon Apr 28, 2015 11:43am

136 Views

Post# 23671842

Patient Home Monitoring Announces Another Record Quarter

Patient Home Monitoring Announces Another Record Quarter of Revenue and Profit, Reports Increase of 28% in Quarter-Over-Quarter Revenue

Annualized Organic Growth in Excess of 255%; Annualized Run-Rate Revenue in Excess of $62,000,000

LOS ANGELES, CALIFORNIA--(Marketwired - April 28, 2015) - Patient Home Monitoring (PHM) (TSX VENTURE:PHM), a profitable company focused on rolling-up annuity-based healthcare service companies in the US and Canada, today provided highlights of its financial results for the second quarter of fiscal 2015.

FYQ2 2015 Highlights

Increased Revenue
· Revenue for the quarter rose to $13,036,000 million, a 28% increase from the previous quarter and a 255% increase year over year.
· Revenues included only 2 months of Black Bear Medical and only 1 month of West Home Health.
· March Revenue exceeded $5,179,000 or $62,148,000 annualized run rate revenue.

Organic Growth Summary
To date, PHM has acquired 5 companies with reported trailing 12-month revenues totaling $40,500,000.
Post acquisition revenues have risen by $21,648,000 in annualized revenues.

Improved Profitability
· Net income (footnote before stock-based comp) rose to $1,618,543, a 23.5% increase from the previous quarter. (2)
· Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) including transactional and nonrecurring cost rose to $2,858,079, a 20.3% increase from the previous quarter. (3)
· Earnings per share (EPS) rose 71% from the previous quarter. (1)

Mergers & Acquisitions
· PHM finalized 2 acquisitions this quarter: Black Bear Medical of Maine and New Hampshire and West Home Health of Virginia.
· PHM has executed 2 LOIs this quarter: a $16.5 million revenue company in Colorado and a $20 million revenue company in Tennessee.
· PHM is in term sheet negotiations with 8 companies, ranging from $3 million in revenues to over $30 million in revenues.
· PHM has increased investment in the M&A team to increase the quantity and quality of potential acquisition targets.

"This is our 8th consecutive quarter of record revenues and profits," reported Michael Dalsin, Chairman of PHM. "Our March revenues of $5,179,000, which translates to annualized revenues of $62,148,000, were higher than expected. Our executive team continues to execute well on integration and cross selling, which is reflected in our financial results."

"Our acquisition and organic growth model is working well in this fast growing market. Our business plan has been proven effective and there have been no recent regulatory changes to prevent us from continuing it" said Mr. Dalsin. "We had a productive quarter in terms of signing LOIs and when closed, we will exceed $100 million in annualized revenues. We are also working toward finalizing the LOI with a $40 million annual revenue business very soon."

Full financial results are available on sedar.com.

PHM is rolling-up a large and fragmented market of small, profitable businesses providing healthcare products and services to chronically ill patients. The companies are acquired for their technical and market expertise in certain product and service lines, as well as their patient databases. Once acquired, PHM works to offer these newly acquired services to its entire patient base, thereby increasing revenue per patient and achieving organic post acquisition revenue growth and profits.

PHM will host an interactive Q&A earnings call at 4p.m. EST on Wednesday, April 29, 2015 to provide in depth data and analysis about the quarterly results.

Participants from PHM will be Michael Dalsin (Chairman), Roger Greene (Vice Chairman), David Hayes (CEO) and Andrew Folmer (CFO).

The details of the call will be released shortly.

Financial professionals are invited to call in and ask questions. To pre-register as a qualified caller, please e-mail dwilson@myphm.com by 5 p.m. EST Tuesday, April 28th, 2015.

About PHM

PHM is an acquisition-oriented, fast-growing and profitable company servicing patients with heart disease and other chronic health conditions. PHM is focused on acquiring companies in a highly fragmented and developing market of small privately-held companies servicing chronically ill patients with multiple disease states caused mainly by age and obesity. Because of the new and highly fragmented nature of the market, PHM is actively identifying and evaluating profitable, annuity-based companies to acquire at favorable prices for their patient databases and technical expertise. PHM's post-acquisition organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient's services and making life easier for the patient. The expected result is growing EPS with each acquisition and growing revenue and profits from the cross selling efforts.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

(1) EPS and Net Profit does not include IFRS Fair Value of options, warrants expense and stock based compensation. EPS growth was calculated using the following information:


Shares Outstanding Q2 2015	Shares Outstanding Q2 2014
203,084,354	128,752,044

Net Profit	Net Profit
$1,618,544	$594,029

EPS	EPS
$0.0079	$0.0046

(2) Net Profit does not include Stock Based Compensation or change in the IFRS Fair Value of options and warrants expense.

(3) Adjusted EBITDA is defined as EBITDA plus Stock Based Compensation.

Forward-Looking Statements
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of PHM and anticipated events or results, are assumptions based on beliefs of PHM's senior management as well as information currently available to it. While these assumptions were considered reasonable by PHM at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue operations, decline of reimbursement rates, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, difficulty integrating newly acquired businesses, low profit market segments as well as general economic, market and business conditions, and could differ materially from what is currently expected.This press release refers non-GAAP and non-IFRS financial measures that do not have standardized meaning prescribed by GAAP or IFRS. PHM's presentation of these financial measures may not be comparable to similarly titled measures used by other companies. These financial measures are intended to provide additional information to investors concerning PHM's performance.